{{Rsnum
|rsid=4269885
|Gene=CNTN5
|Chromosome=11
|position=99994817
|Orientation=plus
|GMAF=0.4573
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CNTN5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 14.2 | 46.9 | 38.9
| HCB | 19.0 | 50.4 | 30.7
| JPT | 21.2 | 39.8 | 38.9
| YRI | 45.6 | 45.6 | 8.8
| ASW | 43.9 | 35.1 | 21.1
| CHB | 19.0 | 50.4 | 30.7
| CHD | 16.7 | 45.4 | 38.0
| GIH | 13.9 | 49.5 | 36.6
| LWK | 40.4 | 45.0 | 14.7
| MEX | 25.9 | 53.4 | 20.7
| MKK | 27.6 | 53.8 | 18.6
| TSI | 16.7 | 43.1 | 40.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4269885
|Name_s=
|Gene_s=CNTN5
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00007. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109360
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4269885
|overall_frequency_n=54
|overall_frequency_d=122
|overall_frequency=0.442623
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}